PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
Multiple myeloma (MM), the second most commonly diagnosed hematologic neoplasm, is the most significant clinical manifestation in a series of plasma cell (PC) dyscrasia. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM), approximately 1% or 10% of which, respectively,...
Main Authors: | Dong Wu, Jiyu Miao, Jinsong Hu, Fangmei Li, Dandan Gao, Hongli Chen, Yuandong Feng, Ying Shen, Aili He |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.684232/full |
Similar Items
-
The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
by: Pawel Robak, et al.
Published: (2021-02-01) -
Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01) -
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells
by: Yu-Chen Cheng, et al.
Published: (2018-01-01) -
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
by: Elia Pancheri, et al.
Published: (2020-09-01) -
Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma
by: Petković Ivan, et al.
Published: (2016-01-01)